Supplementary Materials

The PDF file includes:

  • Materials and methods
  • Fig. S1. MSC2 cells treated with IL4 are transcriptionally similar to TIMC.
  • Fig. S2. Frequency changes of the 15 selected aptamers during HT Cell-SELEX.
  • Fig. S3. Cluster analysis of the 15 aptamers chosen with APTANI.
  • Fig. S4. Aptamers 3, 6, 11, and 14 recognize TIMC among different cancer types and different genetic backgrounds.
  • Fig. S5. Aptamers 3, 6, 11, and 14 show low or no binding to other mouse tissues.
  • Fig. S6. Aptamers 3, 6, 11, and 14 recognize TIMC in patients with HNSCC: Flow cytometry.
  • Fig. S7. Aptamers 3, 6, 11, and 14 recognize TIMC in patients with HNSCC: Image cytometry.
  • Fig. S8. TIMC-specific aptamers do not bind lung or kidney from healthy donors.
  • Fig. S9. TIMC-specific aptamers show no binding for in human tissue microarrays.
  • Fig. S10. Affinity of aptamers 3, 6, 11, and 14 for IL4-treated MSC2 or their putative ligand.
  • Fig. S11. TIMC-specific aptamers are superior to Doxil against 4T1 breast cancer.
  • Fig. S12. TIMC-aptamer approach reduces DOX toxicity.
  • Table S1. Sequence, frequency, and motifs of 15 aptamers selected using APTANI.
  • Table S2. List of oligonucleotides used.
  • Table S3. List of antibodies used.
  • Reference (6877)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Data from primary figures.